Skip to main content

Table 2 Prevalence of comorbidites between subjects with mild AL, moderate-to-severe AL, and normal lung function

From: Comorbidities according to airflow limitation severity: data from comprehensive health examination in Japan

Comorbidity

Normal

n = 11,785

AL

p value

Mild n = 469

Moderate-to-very severe n = 451

Men (n = 6,661)

n = 6,010

n = 257

n = 394

 

 Lumg cancer

9 (0.15)

3 (1.17)

7 (1.78)

<0.001

 Hypertension

2,602 (43.29)

127 (49.42)

210 (53.30)

0.064

 Diabetes and hyperglycemia

1,241 (20.65)

65 (25.29)

102 (22.62)

0.012

 Dyslipidemia

2,887 (48.04)

118 (45.91)

182 (46.19)

0.637

 MetS (JIS)

1,009 (16.79)

44 (17.12)

84 (21.32)

0.068

 MetS (JCCMS)

964 (16.04)

46 (18.11)

68 (17.26)

0.611

 Ischemic heart disease

164 (2.73)

7 (2.72)

14 (3.55)

0.627

 Osteoporosis

8 (0.13)

0 (0)

1 (0.25)

0.684

 Depression and mental disease

17 (0.28)

0 (0)

1 (0.25)

0.692

Women (n = 6,044)

n = 5,775

n = 212

n = 57

 

 Lumg cancer

15 (0.26)

2 (0.94)

1 (1.75)

0.026

 Hypertension

1,886 (32.66)

97 (45.75)

25 (43.86)

<0.001

 Diabetes and hyperglycemia

754 (13.06)

44 (20.75)

9 (15.79)

0.005

 Dyslipidemia

2,433 (42.13)

94 (44.34)

17 (29.82)

0.138

 MetS (JIS)

1,024 (17.73)

51 (24.06)

9 (15.79)

0.057

 MetS (JCCMS)

200 (3.46)

14 (6.60)

2 (3.51)

0.054

 Ischemic heart disease

61 (1.06)

3 (1.42)

0 (0)

0.648

 Osteoporosis

316 (5.47)

19 (8.96)

6 (10.53)

0.027

 Depression and mental disease

15 (0.26)

1 (0.47)

0 (0)

0.779

  1. Data presented are number (percent)
  2. Ischemic heart disease; including angina pectoris and myocardial infarction Airflow limitation (AL) was dfined as FEV1/FVC < 0.7
  3. Hypertension; antihypertensive medication use or systolic blood pressure 130 mmHg or diastolc blood pressure 85 mmHg Diabetes and hypergfycemia; blood glucose-lowerning medication use or elevated fasting glucose 110 Dyslipidemia; medication use or triglycerides 150 mg/dl, HDL-C < 40 mg/dl or LDL-C 140 mg/dl
  4. AL airflow limitation, MetS metabolic syndrome, JIS Joint Interim Statement, JCCMS Japanese Committee of Criteria for MetS